Welcome to our dedicated page for COGNITION THERAPEUTICS SEC filings (Ticker: CGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cognition Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing zervimesine for neurodegenerative diseases. Its Form 8-K reports cover financial results, Regulation FD presentations, clinical-development announcements, FDA meeting disclosures, and material agreements, including an at-the-market common-stock sales arrangement.
Proxy materials disclose annual meeting and stockholder voting matters, while registration and current-report disclosures identify the company’s Delaware corporate status, emerging growth company reporting status, and Nasdaq-listed common stock. The filings also provide formal records of capital-structure activity, governance processes, and risk areas associated with clinical research, regulatory review, grant funding, and the financing needs of a development-stage biotechnology company.
Cognition Therapeutics CEO Lisa Ricciardi reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 5,850 shares of common stock at $1.12 per share to cover tax obligations. After this, she directly owns 1,706,676 shares, plus 38,851 shares held indirectly by her spouse.
COGNITION THERAPEUTICS INC Chief Financial Officer John Brendan Doyle reported a tax-related share disposition. On the vesting of restricted stock units, the issuer withheld 1,560 shares of common stock at $1.12 per share to cover tax obligations, leaving Doyle with 617,509 directly owned shares after the transaction.
COGNITION THERAPEUTICS INC Chief Medical Officer Anthony Caggiano reported a tax-related share disposition. On 2026-02-15, he had 4,680 shares of common stock withheld at $1.12 per share to cover tax obligations from vesting restricted stock units. After this tax-withholding transaction, he directly owned 864,906 shares of common stock.
Cognition Therapeutics CEO and President Lisa Ricciardi reported equity compensation and related tax withholding transactions in company stock. On February 3, 2026, she acquired 800,000 RSU-based shares of common stock at $0.00 per share, reflecting a stock award.
On the same day, the company withheld 26,036 shares at $1.12 to cover taxes tied to RSU vesting, and on February 4, 2026 withheld another 51,704 shares at $1.03 for the same purpose. After these transactions, she directly beneficially owned 1,712,526 shares, with an additional 38,851 shares held indirectly by her spouse.
Cognition Therapeutics (CGTX) Chief Financial Officer John Brendan Doyle reported equity compensation and related tax withholding transactions. On February 3, 2026, he acquired 200,000 shares of Common Stock at $0.00 per share, representing restricted stock units (RSUs), increasing his direct holdings to 645,990 shares.
On February 4, 2026, 26,921 shares of Common Stock were withheld at $1.03 per share to cover tax obligations tied to RSU vesting, leaving Doyle with 619,069 directly owned shares of Cognition Therapeutics Common Stock.
Cognition Therapeutics Chief Medical Officer Anthony Caggiano reported equity compensation and related tax withholding in company stock. On 02/03/2026, he acquired 400,000 shares of Common Stock at $0.00 per share, representing settlement of restricted stock units, each equal to one share of Common Stock upon vesting.
On the same date, 11,488 shares were withheld at $1.12 per share, and on 02/04/2026 a further 26,919 shares were withheld at $1.03 per share, to cover tax obligations tied to the RSU vesting. After these transactions, Caggiano directly owned 869,586 shares of Cognition Therapeutics Common Stock.
Cognition Therapeutics, Inc. filed a current report to note that it has issued a press release about completing a Tye C meeting with the U.S. Food and Drug Administration for its drug candidate zervimesine in dementia with Lewy bodies. The company is furnishing this press release as an exhibit to the report, providing investors with an official update on this regulatory interaction.
Cognition Therapeutics established a new at-the-market stock offering program that permits it to sell up to $75,000,000 of common shares through Jefferies as sales agent or principal. Sales, if any, will be made under a prospectus supplement filed on December 18, 2025, and effected as at-the-market transactions or negotiated deals under a Form S-3 registration statement.
The company also terminated its prior at-the-market program started in 2022 with Cantor Fitzgerald and B. Riley, which had authorized up to $40,000,000 of sales and had approximately $12,500,000 of capacity remaining at termination. Cognition Therapeutics incurred no termination penalties and will no longer sell shares under the 2022 program.
Cognition Therapeutics, Inc. is establishing a shelf program that would allow it to offer and sell up to $300,000,000 of common stock, preferred stock, debt securities, warrants, subscription rights and units from time to time. Within this, it has a separate sales agreement with Jefferies LLC to issue and sell up to $75,000,000 of common stock through an at-the-market offering. The company intends to use any net proceeds for general corporate purposes, including research and clinical development, working capital and capital expenditures.
Cognition is a clinical‑stage biopharmaceutical company developing small‑molecule therapies for age‑related degenerative diseases, led by zervimesine (CT1812) for Alzheimer’s disease, dementia with Lewy bodies and geographic atrophy. Multiple Phase 2 studies have met primary safety and tolerability endpoints and showed signals of clinical and biomarker benefit. As of September 30, 2025, it had 88,268,078 common shares outstanding and remains an emerging growth and smaller reporting company under U.S. securities rules.